cfDNA Methylation for Liver Cancer Recurrence Detection

Plain-language summary

This study examines measuring the methylation of the GNB4 and Riplet genes on cell-free DNA (cfDNA) circulating in the blood to detect recurrence of liver cancer. Patients with a primary liver cancer diagnosis can take part. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Wuhan Ammunition Life-tech Co., Ltd

Intervention

plasma GNB4 and Riplet genes methylation detection

Start date

9/2/2025

Estimated completion

12/31/2027

Countries

China

Related genes

Locations

• Wuhan, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Primary liver cancer

Exclusion Criteria:

* Concurrent other malignant tumors;
* Ineligible for hepatectomy, liver transplantation, ablation, or TACE therapy;
* Negative methylation status prior to treatment.